AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06179160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered at protocol defined dose.
Study NCT06179160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab will be administered at protocol defined dose.
Study NCT06700200 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: taVNS
Description: transauricular vagus nerve stimulation
Study NCT06700200 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: taVNS
Description: transauricular vagus nerve stimulation
Study NCT06698965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy （Etoposide and Carboplatin）
Description: Etoposide: 80-100mg/m2, Q3W, intravenous infusion is administered on day 1, 2 and 3 of each cycle.~Carboplatin: AUC=5, Q3W, intravenous infusion is administered on day 1 of each cycle.
Study NCT06698965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy （Etoposide and Carboplatin）
Description: Etoposide: 80-100mg/m2, Q3W, intravenous infusion is administered on day 1, 2 and 3 of each cycle.~Carboplatin: AUC=5, Q3W, intravenous infusion is administered on day 1 of each cycle.
Study NCT06698965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy （Envafolimab）
Description: Envafolimab: 300mg, Q3W, subcutaneous injection is administered on day 1 of each cycle.
Study NCT06698965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy （Envafolimab）
Description: Envafolimab: 300mg, Q3W, subcutaneous injection is administered on day 1 of each cycle.
Study NCT06698965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Trilaciclib: 240mg/m2, Q3W, intravenous infusion should be completed within 4 hours before daily chemotherapy
Study NCT06698523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing exercise
Description: bubble blower used as play toys to facilitate the breathing exercise
Study NCT06698523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deep breathing
Description: pin wheel used as a play toy for achievement of breathing exercise
Study NCT06699550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haptonomy
Description: The session transitioned to energy work and dream visualization. The researcher and the pregnant participant placed their left hands on each other's hearts. The goal was for the participants to feel the energy flowing between them, sense their hearts, open their third eye, and prepare their hands. This exercise aimed to enhance the pregnant participant's confidence in her own emotions and body by recognizing her feelings and physical sensations. Next, the researcher and the pregnant participant placed their right hands on the participant's forehead and their left hands over their hearts. This positioning facilitated the pregnant participant in visually sensing the presence of her baby. It was intended to promote communication between the mother and her baby at both a physical and spiritual level.
Study NCT06699550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction Program
Description: Participants were introduced to each other and provided with information related to pregnancy. The Mindfulness-Based Stress Reduction Program (MBSR) was introduced. The participants shared their levels of well-being, stress, coping mechanisms for fear of childbirth, and their expectations from the MBSR program. Awareness of habitual behaviors was facilitated. Afterwards, breath-focused meditation and dried fruit meditation were practiced. Participants were encouraged to maintain awareness of activities performed at any time during the day. Lastly, body scan meditation was taught, and participants were instructed to repeat the practice throughout the week using audio recordings.
Study NCT06700083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6934 injection
Description: SHR-6934 injection
Study NCT06416358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALMB-0168
Description: ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
Study NCT06414135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relma-cel
Description: All participants will receive Relma-cel once at different dose levels: 25×10\^6 CAR+ T cells、50×10\^6 CAR+ T cells、75×10\^6 CAR+ T cells
Study NCT06170463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: Met Group Received metformin hydrochloride 500 mg tab 3 times Daily
Study NCT06170463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MI/DCI combination in 40:1 ratio
Description: MI-group received MI/DCI combination in 40:1 ratio twice daily
Study NCT06170463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination of Metformin hydrochloride and MI/DCI
Description: MM Group Received both Met and MI Groups Treatment
Study NCT06090981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bovine surfactant
Description: Dose of surfactant: 4ml/kg Type of surfactant: 4ml/kg
Study NCT06179160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMNabP
Description: GEMNabP will be administered at protocol defined dose.
Study NCT06179160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX will be administered at protocol defined dose.
Study NCT05719441 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: 10 mg/kg intravenous infusion over approximately 15 to 30 minutes once at entry
Study NCT05719441 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: 5 mg/kg intravenous infusion over approximately 30 to 60 minutes once at entry
Study NCT05719441 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection USP, 0.9%
Study NCT05719441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART
Description: Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet orally once daily with or without food
Study NCT05719441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ART
Description: Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablet orally once daily with or without food
Study NCT05596162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Therapy
Description: Exercise with Blood Flow Restriction
Study NCT05596162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy
Description: Exercise without Blood Flow Restriction
Study NCT06700083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6934 placebo
Description: SHR-6934 placebo
Study NCT06655298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: US guided block
Description: Group Q; (28 patients) Quadratus lumborum block group; patients will receive general anesthesia initially then bilateral QLB type III (anterior subcoastal approach) with a volume of 30 mL of bupivacaine 0.25% for each side taking care that the patient does not receive a local anesthetic dose higher than the maximum allowed (2.5 mg/kg) \[9\].~✓ Group E; (28 patients) Erector spinae plane block; patients will receive general anesthesia initially then bilateral ESPB with a volume of 30 mL of bupivacaine 0.25 % for each side taking care that the patient does not receive a local anesthetic dose higher than the maximum allowed (2.5 mg/kg
Study NCT06526364 — intervention group
Intervention type: OTHER
Intervention: All participants will be asked to provide data and samples for collection and analysis.
Description: During the first year, data related to demographics, lifestyle, clinical examinations will be collected at baseline, at 6 months (optional) and at 12 months. PROs, cognitive and motor assessments will be performed using the Healios+Me smartphone app. Additionally, participants will be asked to provide biological samples (i.e., blood, cerebrospinal fluid and stool, saliva and hair) and imaging data (if performed as per standard of care). One unscheduled visit may be performed in case the participant comes to the hospital with the occurrence of flare or for a treatment change.~A long-term follow-up (FU, starting from month 12 and up to 4 years after month 12) is foreseen in this study. During the long-term FU medical data are collected either every 6 month or on a yearly basis, and PROs are collected every 6 months. Whether study visits are conducted in 6- or 12-monthly intervals depends on the schedule of the study visits for the Swiss MS cohort (SMSC).
Study NCT05082909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probenecid
Description: Addition of 500mg QDS to oral penicillin.
Study NCT06778304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal F
Description: The reference formulation is the recombinant human follicle-stimulating hormone injection (Gonal-f®) originally developed and produced by Merck Serono
Study NCT06778304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: jzb30
Description: The test formulation is the recombinant human follicle-stimulating hormone injection (code: JZB30) produced by Shanghai Jingze Biotechnology Co., Ltd./Chengdu Jingze Biopharmaceutical Co., Ltd.
Study NCT06777940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kegel exercises
Description: It consists of 25 patients who will receive Kegel exercises with Myokinetic active release of trigger points in quadratus lumborum, rectus abdominis and gluteus medius. Patient will be in lying position with empty bladder. Ask patient to tight pelvic floor muscle group and hold tight from 3-5 seconds Then relax muscle group from 3-5 seconds with Myokinetic therapy targeted at releasing muscle of quadratus lumborum, rectus abdominis and gluteus medius release was applied passively by sustained pressure for 8-10 seconds. This protocol consisted of three sets with 2 minutes of rest..Participants will be asked to perform exercise 30 times each session following hold and relax of muscle group for 3-5 seconds
Study NCT06779110 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Using OCT to guide PCI in ISR
Study NCT06779006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help acceptance and commitment therapy with behavioral activation
Description: Internet-based self-help acceptance and commitment therapy with behavioral activation
Study NCT06778993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding Education Program Accompanied by a Wearable (Hybrid) Simulator
Description: This training is conducted in both theoretical and practical formats. The theoretical training consists of two sessions, each lasting 25 minutes, with a 10-minute break in between, totaling 60 minutes. Following the theoretical training, simulation-based skill training is conducted. This phase also comprises two sessions of 25 minutes each, with a 10-minute break, making a total duration of 60 minutes.
Study NCT06779045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK-1286
Description: Cohort 1: 1 mg/d QD AK-1286 PO,DLT observation period: 21 days. Cohort 2: 2 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 3: 4 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 4: 5 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 5: 16 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 6: 24 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 7: 36 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 8: 50 mg/d BID AK-1286 PO,DLT observation period: 21 days.
Study NCT06779084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: contemporary fasting principle
Description: (clear fluids for up to 2 hours before anesthesia)
Study NCT06779084 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional fasting time
Description: (≥ 8 hours)
Study NCT06777953 — intervention group
Intervention type: OTHER
Intervention: Erector Spinae (ESP) Block with Lidocaine/Bupivacaine
Description: This study is to retrospectively compare the analgesic efficacy and impact on postoperative recovery of popliteal sciatic nerve blocks and Lumbar-Sacral Erector Spinae Plane blocks administered for postoperative pain management in tibial fractures.
Study NCT06777953 — intervention group
Intervention type: OTHER
Intervention: Popliteal Sciatic Nerve Block
Description: This study is to retrospectively compare the analgesic efficacy and impact on postoperative recovery of popliteal sciatic nerve blocks and Lumbar-Sacral Erector Spinae Plane blocks administered for postoperative pain management in tibial fractures.
Study NCT06778954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm I (Peritoneal application group)
Description: At the end of gastrectomy, during closure of incision, peritoneum and fascia are closed by suture, layer by layer. Skin approximation is doen with skin stapler. Ropivacaine-Poloxamer 407 hydrogel is applied on space between peritoneum and fascia in Arm I.
Study NCT06778954 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Arm I (Peritoneal application group)
Description: At the end of gastrectomy, during closure of incision, peritoneum and fascia are closed by suture, layer by layer. Skin approximation is doen with skin stapler. Ropivacaine-Poloxamer 407 hydrogel is applied on space between peritoneum and fascia in Arm I.
Study NCT06778954 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Arm II (Subcutaneous injection group)
Description: At the end of gastrectomy, during closure of incision, peritoneum and fascia are closed by suture, layer by layer. Skin approximation is doen with skin stapler. Ropivacaine-Poloxamer 407 hydrogel is injected on subcutaneous area in Arm II.
Study NCT06778954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm II (Subcutaneous injection group)
Description: At the end of gastrectomy, during closure of incision, peritoneum and fascia are closed by suture, layer by layer. Skin approximation is doen with skin stapler. Ropivacaine-Poloxamer 407 hydrogel is injected on subcutaneous area in Arm II.
Study NCT06778720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy with over-the ear headphones
Description: Eligible patients undergoing VATS procedure can have music therapy as an intervention to reduce pain levels after surgery and improve outcomes.
Study NCT06779617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEPSys
Description: The SEPSys Score is a clinical decision support tool for predicting the risk of developing sepsis in the next 4 hours. The SEPSys Score produces a 1-4, color-coded risk, where 4 (red) is the highest risk and 1 (green) is the lowest risk.
Study NCT06779617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESCUE
Description: The RESCUE Score is a clinical decision support tool for predicting the risk of patient experiencing clinical deterioration (cardiac arrest, rapid response team call, death, or unplanned increase in care) in the next 4 hours. The RESCUE Score produces a 1-4, color-coded risk, where 4 (red) is the highest risk and 1 (green) is the lowest risk.
Study NCT06778395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexlansoprazole 60 mg
Description: once daily for 8 weeks
Study NCT06778395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan 20 mg bid
Description: twice daily for 8 weeks
Study NCT06777758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam
Study NCT05547399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered orally as a tablet or capsule
Study NCT06650748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: Dalpiciclib, oral administration, 125g each time, once daily, days 1-21, with a 28-day cycle (3 weeks on/1 week off). Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.
Study NCT06650748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg, oral, once daily (continuously), with a 28-day cycle. Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage
Study NCT06657391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant humanized anti-CD25 monoclonal antibody
Description: The intervention group received 4 doses of recombinant humanized anti-CD25 monoclonal antibody on days +7, +14, +28, and +42 after transplantation, with a recommended dose of 1 mg/kg.
Study NCT06658990 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: buccal acupuncture
Description: ultrasound positioning assisted buccal acupuncture
Study NCT05082909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Addition of 500mg QDS to oral penicillin.
Study NCT05141695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: therapeutic repetitive peripheral magnetic stimulation
Description: Patients in the treatment group will receive peripheral magnetic stimulation therapy for the upper extremity arm/forearm spastic muscles on the hemiplegic side for a total of ten sessions once a day, five sessions a week, for two weeks, each session lasting ten minutes. Ten sessions of stretching exercises will be applied to all patients once a day, five sessions a week, with each session lasting 20 minutes.
Study NCT05141695 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive peripheral magnetic stimulation
Description: rPMS will not be given to the sham group, the device will not be operated, the probe of the device will be positioned in the same way as the patients in the treatment group for ten minutes, and the sounds recorded during the operation of the device will be heard by the patients. Patients and evaluators will not know which group the patients are in. Ten sessions of stretching exercises will be applied to all patients once a day, five sessions a week, with each session lasting 20 minutes.
Study NCT06513962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard chemotherapy
Study NCT06513962 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06513962 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06698952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The intervention group will engage with SPI-Bot, a conversational agent designed to deliver cognitive and behavioral strategies for managing psychological symptoms through fully automated interactions. SPI-Bot operates on a template-based platform with predefined dialogue options, utilizing natural language processing technology. The intervention spans eight weeks and includes key components such as psychoeducation, cognitive restructuring, relaxation training, activity scheduling, problem-solving skills training, and social skills training. Participants will complete one session per week over the eight-week period. Participants will receive weekly contact from the research team to report AIS symptoms, receive homework reminders, and address any intervention-related questions.
Study NCT06658990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Sufentanil is used after surgery
Study NCT06658210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soft tissue mobilization with pelvic floor muscle exercises
Description: Group A will receive soft tissue mobilization and pelvic floor muscle exercises. Soft tissue mobilization technique will include abdominal myofascial release/trigger point release and deep scar mobilization to decrease pain and improve scar mobility
Study NCT06658210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soft tissue mobilization without pelvic floor muscle exercises
Description: Group B will receive soft tissue mobilization technique without pelvic floor exercises.
Study NCT06658444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phonophoresis
Description: Pulsed ultrasound will be used at a frequency of 1 MHz with an intensity of 0.5 W/ cm2 for 5 minutes.
Study NCT06698952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Participants in the control group will interact with a different generative chatbot, engaging in casual conversations at a similar dosage to ensure balanced attention and interaction effects.
Study NCT06513962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06513962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06513962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06513962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06513962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Pamoate
Description: Given IM